RVTY Stock Summary and Trading Ideas (Revvity | NYSE:RVTY)

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Revvity trades on the NYSE stock market under the symbol RVTY.

As of December 26, 2025, RVTY stock price declined to $96.75 with 516,074 million shares trading.

RVTY has a beta of 0.95, meaning it tends to be less sensitive to market movements. RVTY has a correlation of 0.20 to the broad based SPY ETF.

RVTY has a market cap of $10.97 billion. This is considered a Large Cap stock.

Last quarter Revvity reported $699 million in Revenue and $1.18 earnings per share. This fell short of revenue expectation by $-787,052 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that RVTY belongs to (by Net Assets): VTI, VOO, VB, VBR, IVV.

RVTY has underperformed the market in the last year with a price return of -13.7% while the SPY ETF gained +16.0%. However, in the short term, RVTY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.2% vs +4.6% return in SPY. But in the last 2 weeks, RVTY shares have been beat by the market, returning -3.7% compared to an SPY return of +1.5%.

RVTY support price is $94.81 and resistance is $98.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RVTY shares will trade within this expected range on the day.